JP7582961B2 - ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤 - Google Patents
６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤 Download PDFInfo
- Publication number
- JP7582961B2 JP7582961B2 JP2021558405A JP2021558405A JP7582961B2 JP 7582961 B2 JP7582961 B2 JP 7582961B2 JP 2021558405 A JP2021558405 A JP 2021558405A JP 2021558405 A JP2021558405 A JP 2021558405A JP 7582961 B2 JP7582961 B2 JP 7582961B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound represented
- solid preparation
- preparation containing
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019209630 | 2019-11-20 | ||
| JP2019209630 | 2019-11-20 | ||
| PCT/JP2020/042889 WO2021100728A1 (ja) | 2019-11-20 | 2020-11-18 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021100728A1 JPWO2021100728A1 (https=) | 2021-05-27 |
| JP7582961B2 true JP7582961B2 (ja) | 2024-11-13 |
Family
ID=75980561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558405A Active JP7582961B2 (ja) | 2019-11-20 | 2020-11-18 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4062973A4 (https=) |
| JP (1) | JP7582961B2 (https=) |
| WO (1) | WO2021100728A1 (https=) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652752A (zh) | 2002-03-14 | 2005-08-10 | 欧罗赛铁克股份有限公司 | 盐酸纳曲酮组合物 |
| CN101406474A (zh) | 2008-02-28 | 2009-04-15 | 云南绿野生物医药有限公司 | 纳美芬注射液及其制备方法 |
| CN101732243A (zh) | 2008-11-26 | 2010-06-16 | 重庆医药工业研究院有限责任公司 | 一种稳定的甲基纳曲酮注射液及其制备方法 |
| WO2013172297A1 (ja) | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤 |
| CN103877016A (zh) | 2014-04-11 | 2014-06-25 | 成都苑东药业有限公司 | 一种盐酸纳洛酮注射液药物组合物及其制备方法 |
| US20160067339A1 (en) | 2012-06-05 | 2016-03-10 | Neuroderm, Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
| JP2018500350A (ja) | 2014-12-23 | 2018-01-11 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | アポモルヒネの結晶形態およびその使用 |
| JP2018065775A (ja) | 2016-10-21 | 2018-04-26 | 東洋カプセル株式会社 | ナルフラフィン塩酸塩を含有するカプセル充填用組成物、軟カプセル剤及びその製造方法 |
| WO2018124062A1 (ja) | 2016-12-26 | 2018-07-05 | 塩野義製薬株式会社 | 含量均一性を改善した製剤の製造方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100514963B1 (ko) * | 1997-07-11 | 2005-09-15 | 도레이 가부시끼가이샤 | 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물 |
| DE19813661A1 (de) | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| CA2784407A1 (en) | 2009-12-17 | 2011-07-14 | Cima Labs Inc. | Abuse-resistant formulations |
| RU2607084C2 (ru) | 2010-11-12 | 2017-01-10 | Сионоги Энд Ко., Лтд. | Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения |
| JP6030357B2 (ja) | 2012-07-03 | 2016-11-24 | サンスター株式会社 | オレウロペイン含有組成物 |
| WO2018021518A1 (ja) * | 2016-07-29 | 2018-02-01 | 東レ株式会社 | 光安定性の向上した固形製剤 |
-
2020
- 2020-11-18 JP JP2021558405A patent/JP7582961B2/ja active Active
- 2020-11-18 WO PCT/JP2020/042889 patent/WO2021100728A1/ja not_active Ceased
- 2020-11-18 EP EP20890315.3A patent/EP4062973A4/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652752A (zh) | 2002-03-14 | 2005-08-10 | 欧罗赛铁克股份有限公司 | 盐酸纳曲酮组合物 |
| CN101406474A (zh) | 2008-02-28 | 2009-04-15 | 云南绿野生物医药有限公司 | 纳美芬注射液及其制备方法 |
| CN101732243A (zh) | 2008-11-26 | 2010-06-16 | 重庆医药工业研究院有限责任公司 | 一种稳定的甲基纳曲酮注射液及其制备方法 |
| WO2013172297A1 (ja) | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤 |
| US20160067339A1 (en) | 2012-06-05 | 2016-03-10 | Neuroderm, Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
| CN103877016A (zh) | 2014-04-11 | 2014-06-25 | 成都苑东药业有限公司 | 一种盐酸纳洛酮注射液药物组合物及其制备方法 |
| JP2018500350A (ja) | 2014-12-23 | 2018-01-11 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | アポモルヒネの結晶形態およびその使用 |
| JP2018065775A (ja) | 2016-10-21 | 2018-04-26 | 東洋カプセル株式会社 | ナルフラフィン塩酸塩を含有するカプセル充填用組成物、軟カプセル剤及びその製造方法 |
| WO2018124062A1 (ja) | 2016-12-26 | 2018-07-05 | 塩野義製薬株式会社 | 含量均一性を改善した製剤の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4062973A1 (en) | 2022-09-28 |
| JPWO2021100728A1 (https=) | 2021-05-27 |
| WO2021100728A1 (ja) | 2021-05-27 |
| EP4062973A4 (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7216055B2 (ja) | 医薬組成物 | |
| ES2535478T3 (es) | Composición farmacéutica | |
| RU2527766C2 (ru) | Таблетки и гранулированные порошки, содержащие 6-фтор-3-гидрокси-2-пиразинкарбоксамид | |
| CN1913876B (zh) | 含药物的颗粒和包含这种颗粒的固体制剂 | |
| TWI788557B (zh) | 穩定性優異的固態製劑 | |
| CN110603035A (zh) | 具有改善的水溶解度及生物利用率的组合物 | |
| EA036278B1 (ru) | Фармацевтическая композиция | |
| AU2023201826A1 (en) | Solid formulation having excellent stability | |
| JP2022082720A (ja) | 含量均一性を改善した製剤の製造方法 | |
| JP7359764B2 (ja) | ジアミン誘導体を含む顆粒剤 | |
| JP5818219B2 (ja) | ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤 | |
| TWI574705B (zh) | Capsules | |
| US20210077451A1 (en) | A stable oral pharmaceutical composition of ferric citrate | |
| JP7582961B2 (ja) | ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤 | |
| JP5275815B2 (ja) | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 | |
| JP5807642B2 (ja) | アトルバスタチン含有医薬錠剤 | |
| JPWO2019230937A1 (ja) | 溶出性に優れた経口固形製剤 | |
| CN113164436A (zh) | 药物组合物 | |
| JP7745371B2 (ja) | ゾニサミド原薬粒子およびその用途 | |
| JP2005139086A (ja) | 速崩壊製剤 | |
| JP6176840B2 (ja) | フェキソフェナジン顆粒製剤及びその製造方法 | |
| KR20080071557A (ko) | 고형 제제 및 제제 조성물 | |
| JP2017081850A (ja) | 造粒物及びこれを含む経口製剤並びに造粒物及び経口製剤の製造方法 | |
| TW202510841A (zh) | 賦形劑造粒物 | |
| US20240091367A1 (en) | Orally disintegrating palatable formulations of drotaverine and method of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230907 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20231019 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240919 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241022 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241031 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7582961 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |